The absence of a common nomenclature was a major hindrance to cancer research. To remedy this situation, researchers in our Team, in collaboration with the International Agency for Research on Cancer (IARC) and the CEA-Jacob Institute, have developed a new nomenclature convention for peritumoral tissues. This major advance will allow:
-
To unify global research: By using a common language, scientists around the world will be able to compare their results and accelerate discoveries.
-
To better understand the tumor environment: Peritumoral tissues, often neglected, could reveal keys to developing new, more effective treatments.
-
To improve prognosis: Better characterization of these tissues will allow for a better assessment of the risk of recurrence and for tailoring treatments to each patient.
An innovative approach to combating cancerThis innovative initiative opens up new perspectives for cancer research. By adopting this nomenclature, the scientific community is taking a decisive step towards more effective precision medicine. The researchers also propose, in their article published in the British Journal of Cancer, to add additional information associated with the collection of clinical samples, in order to enrich the bioinformatics analysis of the data.
In conclusion, this new nomenclature represents new hope for cancer patients. By facilitating collaboration between researchers and accelerating basic research, it will help improve the treatment and prognosis of many forms of cancer.